← Back to headlines
Ars Pharmaceuticals Awaits CVS Caremark Decision Amid Retail Program Expansion
Ars Pharmaceuticals is awaiting a decision from CVS Caremark regarding its product while simultaneously expanding its $199 retail access program.
16 May, 01:32 — 16 May, 01:32
Sources
Showing 1 of 1 sources
